Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
piclidenoson · 3 trials · 4 indications
Improvement of psoriasis by 75% or more
Improvement of psoriasis by physicians' judgment
All adverse events occurring the trial will be recorded
The primary end-point is to assess whether treatment for 6 months with piclidenoson improves the functioning of renal proximal tubular cells (PTCs), as assessed by the increase in 99mTc-DMSA uptake as compared to Baseline
Proportion of subjects alive and free of respiratory failure (defined as need for non-invasive or invasive mechanical ventilation, high-flow oxygen, or extracorporeal membrane oxygenation) at Day 29
Proportion of subjects alive and discharged to home without need for supplemental oxygen at Day 29
Proportion of patients experiencing AEs
| Arm | Type | Description |
|---|---|---|
| Piclidenoson treatment | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Piclidenoson (CF101) open-label treated patients | EXPERIMENTAL | Piclidenoson will be administered orally at a dose of 3 mg twice per day for 6 months |
| Piclidenoson | EXPERIMENTAL | Piclidenoson 2 mg every 12 hours orally added to standard of care |
| Name | Type | Description |
|---|---|---|
| piclidenoson | DRUG | Piclidenoson is a selective A3AR agonist, supplied as tablets. |
| Placebo | DRUG | Inactive control |
Inclusion Criteria: 1. Male or female, 18 years and above; 2. Diagnosis of moderate-to-severe chronic plaque-type psoriasis with BSA involvement ≥10%; 3. PASI score ≥12 at the Screening and Baseline visits; 4. Static PGA ≥3 at the Screening and Baseline visits; 5. Candidate for systemic treatment o...
Piclidenoson is an investigational small molecule being studied for COVID-19, Lowe Syndrome, and moderate-to-severe plaque psoriasis. It is developed by Can-Fite Biopharma Ltd (CANF). The drug is in Phase 2 clinical development for COVID-19 and Lowe Syndrome, and a Phase 3 study is planned for plaque psoriasis.
Piclidenoson is a small molecule developed by Can-Fite Biopharma Ltd (CANF). Its molecular target has not been disclosed in the available information. The drug is being investigated for COVID-19, Lowe Syndrome, and plaque psoriasis, but its specific mechanism of action is not publicly detailed.
Piclidenoson is developed by Can-Fite Biopharma Ltd, a biopharmaceutical company traded under the ticker CANF. The company is conducting clinical trials of Piclidenoson for COVID-19, Lowe Syndrome, and plaque psoriasis.
Piclidenoson is in Phase 2 clinical development for COVID-19 and Lowe Syndrome. A Phase 3 study for moderate-to-severe plaque psoriasis is planned but has not yet started recruiting. The drug is investigational and not approved by regulatory authorities.
Piclidenoson has one completed Phase 2 trial for COVID-19 (NCT04333472) with 6 participants. Two trials are not yet recruiting: a Phase 3 study for plaque psoriasis (NCT06643260) with 705 participants and a Phase 2 pilot study for Lowe Syndrome (NCT07410455) with 5 participants.
Piclidenoson is not known by alternative names in the available information. It is referred to solely as Piclidenoson in clinical trial records and company communications from Can-Fite Biopharma Ltd.